Prognostic implications of left ventricular hypertrophy

American Heart Journal

Volumn 141, Issue 3, 2001, Pages 334-341

  Vakili, Babak A ^a   Okin, Peter M ^b   Devereux, Richard B ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIALYSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MALE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RACE; SEX DIFFERENCE;

EID: 0035089266     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.113218     Document Type: Article

References (47)

1. Left ventricular function and regression of left ventricular hypertrophy in essential hypertension
2. Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The Framingham Heart study
3. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension
4. Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects
5. Prognostic significance of serial changes in left ventricular mass in essential hypertension
6. A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: The Framingham Study
7. Clinical significance and prognostic importance of left ventricular hypertrophy in non-Q-wave acute myocardial infarction
8. Left ventricubr hypertrophy and mortality in hypertension: An analysis of data from the Glasgow Blood Pressure Clinic
9. Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men
10. Left ventricular hypertrophy on electrocardiogram: Prognostic implications from a 10-year cohort study of older subjects: A report from the Bronx Longitudinal Aging Study
11. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension
12. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
13. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
14. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment
15. The prognosis of essential hypertension treated conservatively
16. Left ventricular hypertrophy patterns and prognosis: Experience postinfarction in the Coronary Drug Project
17. Long-term prognosis after acute myocardial infarction in patients with left ventricular hypertrophy on the electrocardiogram: SPRINT Study Group
18. Left ventricular hypertrophy: Effect on survival
19. Electrocardiographic left ventricular hypertrophy in patients with suspected acute cardiac ischemia-its influence on diagnosis, triage, and short-term prognosis: A multicenter study
20. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women
21. The clinical course of left ventricular hypertrophy in dialysis patients
22. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease
23. Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension
24. Left ventricular hypertrophy has a greater impact on survival in women than in men
25. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
26. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension
27. What is normal blood pressure? Comparison of ambulatory pressure level and variability in patients with normal or abnormal left ventricular geometry
28. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults
29. Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults
30. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass
31. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy
32. Prognosis of left ventricular geometric patterns in the Framingham Heart Study
33. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease
34. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among blacks
35. Management of essential hypertension in patients with difference degrees of left ventricular hypertension: Multicenter trial
36. Prognostic implicatins of baseline electrocardiographic features and their serial changes in subject with left ventricular hypertrophy
37. Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study
38. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and of the impact of overweight
39. Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and of their capacity to predict cardiovascular risk
40. Prediction of mortality risk by different methods of indexation for left ventricular mass
41. Elevated ambulatory with normal clinic blood pressure ("white coat normotension") is associated with cardiac and arterial target organ damage
42. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients: The losartan intervention for endpoint (LIFE) reduction in hypertension study
43. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension
44. Publication bias in clinical research
45. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials
46. Criteria for an informative trial of left ventricular hypertrophy regression
47. Surrogate end points in clinical trials: Are we being misled?